The Advocate: Supporting the Patient Voice is excited to announce the results of its 2024 US Focused Patient Advocacy report.
WEST CHESTER, PA, July 24, 2024 /24-7PressRelease/ — The report provides an in-depth look at feedback from Patient Advocacy Organizations & Professional Societies/Associations and their relationship with the pharmaceutical community. This information will help stakeholders understand new & innovative ways they can best work with Patient Advocacy Organizations & Professional Societies/Associations to improve healthcare for all patients. The Advocate would like to thank their many sponsors in the pharmaceutical community for making this report possible & for the respondents who gave their time & feedback!
• Out of 100+ companies in the mix, J&J ranked #1 for advocacy with five out of five 1st place rankings. J&J is noted for “moving beyond patient centricity to patient partner”, their “willingness to collaborate with patient advocacy organizations beyond funding” and “taking a holistic approach to building relationship and identifying ways to work together for patients”.
• Amgen continued to show significant improvement and moved up in four out of five benchmarking categories. Patient advocates noted Amgen is “highly innovative and forward thinking’ and how Amgen is “engaged at several levels to work with patient advocacy groups to listen, learn and understand what is needed to ensure they are advancing patient treatments”.
• Since 2019 Pfizer has remained consistent, placing 2nd in the areas of Advancing Patient Treatment and Patient/Professional Group Relations. Pfizer is noted for “obtaining patient perspectives for advancing care and in helping access to care” and their “commitment to patient support and education advancement”.
• Sanofi has shown improvement in many measures within our report. Patient advocates noted “patient engagement is second to none” and Sanofi “fosters education of health equity by forming communities of practice groups among patient organizations”.
• Other organizations of note include: AstraZeneca showed improvement in the area of Policy Support, Eli Lilly came out on top with Neurology groups, Merck showed impressive rankings with Non-disease Specific groups, and Bristol-Myers Squibb led the way with Immunology groups.
The Advocate: Supporting the Patient Voice’s goal is to understand the relationship between advocates & the pharmaceutical industry. It’s their mission to ensure that patients remain at the center of all healthcare decisions – may it be in their doctor’s office, within the walls of the Payer of PBM or up on Capitol Hill. We understand that the pharmaceutical community aligns with their mission in their goals to ensure patients get access to the products they & their physicians have decided. It seeks to serve as a beacon for the pharmaceutical community to always find their way back to the patient by elevating the voice of their loudest supporters – the advocacy organizations. The Advocate does this through a syndicated market research offering for the pharmaceutical community to gain insights into the needs of the patients they serve & the patient advocate organizations they fight side by side with on numerous issues.
The research and expertise of The Advocate allows them to guide today’s pharmaceutical advocacy teams, aid in the development & implementation of patient centricity programs within pharmaceutical companies & consult on the use of the patient voice throughout the products lifecycle. Reach out to Ryan & his team directly with any questions about the current report, or any previous or future reports at Ryan.Evans@BrooksGroupInc.biz or www.TheBrooksGroupOnline.com.
—
For the original version of this press release, please visit 24-7PressRelease.com here
